VPO Exhibitor - About Us

No contacts to display.

News Releases

Mar 18, 2026

Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PD™ 2026 International Conference on Alzheimer's and Parkinson's Diseases

Results Show Continued Safety, Tolerability, and Sustained Clinical Benefit Including Improvements in Function, Physician- and Patient-Reported Outcomes, and Quality-of-Life This Personalized...

Mar 12, 2026

Aspen Receives Adoption of Sasineprocel as the Official Nonproprietary Naming of ANPD001, its Investigational Autologous Cell Therapy for the Treatment of Parkinson's Disease

Approved for Use By both the World Health Organization's International Nonproprietary Names (WHO-INN) and the American Medical Association's United States Adopted Names (AMA-USAN) Council SAN...

Jan 8, 2026

Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients

Facility Enters Qualification to Support Late‑Stage Pivotal Manufacturing and Commercial Readiness SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical‑stage...

Jan 7, 2026

Aspen Neuroscience Appoints Chief Commercial Officer Lisa Johnson-Pratt, M.D. and Welcomes Revati Shreeniwas, M.D., FCCP as Chief Medical Officer to Accelerate Late‑Stage Development and Commercial Readiness

Aspen Neuroscience, Inc., a clinical‑stage biotechnology company pioneering autologous regenerative therapies, today announced two executive leadership appointments: Revati Shreeniwas, M.D.,...

Nov 20, 2025

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round. This...